Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brilanestrant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brilanestrant SCHEMBL29423494 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL766996 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL31540920 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL766995 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767351 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767350 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL17502345 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767216 | 0.99 | ESR1 (0.98) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767215 | 0.99 | ESR1 (0.98) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767218 | 0.99 | ESR1 (0.98) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | claimed |
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RADIUS PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20250326745-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | claimed |
| US-12410189-B2 | Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production | GENENTECH, INC. (US) | 2025-09-09 | — | — | US | claimed |
| US-12398094-B2 | Polymorphic forms of RAD1901-2HCL | RADIUS PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ZENO MANAGEMENT, INC. | 2025-08-21 | — | — | US | claimed |
| US-20250197386-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-06-19 | — | — | US | claimed |
| EP-4568662-A1 | COMPOUNDS FOR TREATING CANCER | Evexta Bio (FR) | 2025-06-18 | — | — | EP | claimed |
| EP-4540256-A2 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | Incyclix Bio, LLC (US) | 2025-04-23 | — | — | EP | claimed |
| CN-111909173-B | Benzoxazepine oxazolidinone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2025-03-04 | — | — | CN | claimed |
| EP-4032102-A1 | METHODS OF TREATMENTS BASED UPON MOLECULAR CHARACTERIZATION OF BREAST CANCER | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-07-27 | — | — | EP | claimed |
| WO-2022133446-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC (US) | 2022-06-23 | — | — | WO | claimed |
| EP-3993785-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | Olema Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| EP-3416632-B1 | USE OF A FASTING MIMICKING DIET TO ENHANCE THE EFFICACY OF ANTIESTROGENS IN CANCER THERAPY | UNIV DEGLI STUDI GENOVA (IT) | 2022-04-13 | — | — | EP | claimed |
| CN-114302722-A | Estrogen receptor antagonist regimens | 奥列马制药公司 | 2022-04-08 | — | — | CN | claimed |
| CN-114209838-A | Medicine for treating KRAS mutant bile duct cancer | 领星生物科技（上海）有限公司 | 2022-03-22 | — | — | CN | claimed |
| WO-2022048527-A1 | USE OF CHIDAMIDE COMBINED WITH ESTROGEN RECEPTOR DOWNREGULATOR IN TREATMENT OF BREAST CANCER | 深圳微芯生物科技股份有限公司 | 2022-03-10 | — | — | WO | claimed |
| US-20220048848-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RADIUS HEALTH, INC. | 2022-02-17 | — | — | US | claimed |
| US-20220044819-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF BREAST CANCER | GENENTECH, INC. | 2022-02-10 | — | — | US | claimed |
| WO-2022026901-A2 | NK ANTAGONISTS FOR CONTRACEPTION | ACER THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | ESR1 11/4885CYP2C9 2288/4885CYP2C19 3214/4885 |
| US-20220048848-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RAD50, RAD1, RAD54L | ESR1 3662/4885CYP2C9 2582/4885CYP2C19 2249/4885 |
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | BRCA1, TP53, RAD1 | ESR1 16/4885CYP2C9 795/4885CYP2C19 544/4885 |
| US-12410189-B2 | Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production | GRIN2C, PPP1CC, CCNC | ESR1 4339/4885CYP2C9 363/4885CYP2C19 174/4885 |
| US-20250326745-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PDPK1 | ESR1 1448/4885CYP2C9 1764/4885CYP2C19 719/4885 |
| US-20250197386-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PDPK1 | ESR1 1448/4885CYP2C9 1764/4885CYP2C19 719/4885 |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ABL1, KRAS, JAK2 | ESR1 1262/4885CYP2C9 1752/4885CYP2C19 1136/4885 |
| US-12398094-B2 | Polymorphic forms of RAD1901-2HCL | RAD50, RAD1, RAD54L | ESR1 3662/4885CYP2C9 2582/4885CYP2C19 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.